Skip to main content
Year archive

IMMUTEP LIMITED — 2025 filings

All 65 regulatory filings released by IMMUTEP LIMITED (IMM) in 2025, sourced directly from the official regulator.

65 Filings
2025 Period
2025 filings (65)
Filing Released Lang
Change in substantial holding 7 pages 349.5KB
Major Shareholding Notification
2025-12-30 English
Positive Update on IMP761 Phase 1 2 pages 235.6KB
Regulatory Filings
2025-12-21 English
TACTI-004 phase III trial enrolment continues at robust pace 2 pages 180.9KB
Capital/Financing Update
2025-12-15 English
Immutep enters into Strategic Collaboration with Dr. Reddy's 3 pages 247.7KB
Capital/Financing Update
2025-12-07 English
Application for quotation of securities - IMM 6 pages 19.1KB
Share Issue/Capital Change
2025-12-04 English
Change of Director's Interest Notice - L Boyce 3 pages 308.8KB
Director's Dealing
2025-12-04 English
Change of Director's Interest Notice - P Meyers 3 pages 305.5KB
Director's Dealing
2025-12-04 English
Change of Director's Interest Notice - R Howard 3 pages 309.4KB
Director's Dealing
2025-12-04 English
New data presentation from AIPAC-003 Phase II for SABCS 2 pages 160.2KB
Investor Presentation
2025-12-01 English
Notification regarding unquoted securities - IMM 7 pages 20.3KB
Share Issue/Capital Change
2025-12-01 English
Immutep AGM 2025 - CEO's Presentation 24 pages 5.3MB
AGM Information
2025-11-26 English
Immutep AGM 2025 - Chairman's Address 3 pages 164.7KB
AGM Information
2025-11-26 English
Results of Meeting 2 pages 182.6KB
Declaration of Voting Results & Voting Rights Announcements
2025-11-26 English
EFTISARC-NEO Phase II results presented at CTOS 2025 3 pages 182.4KB
Regulatory Filings
2025-11-12 English
Immutep Receives A$4.6 million French R&D Tax Incentive 1
Capital/Financing Update
2025-11-02 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 512.3KB
Interim / Quarterly Report
2025-10-28 English
Annual Report filed on Form 20-F 161 pages 9.8MB
Annual Report
2025-10-26 English
Annual Report to shareholders 90 pages 1.3MB
Annual Report
2025-10-23 English
Appendix 4G and Corporate Governance Statement 39 pages 984.9KB
Regulatory Filings
2025-10-23 English
Notice of Annual General Meeting/Proxy Form 26 pages 2.0MB
AGM Information
2025-10-23 English
Primary Endpoint Met in STS Trial - presented at ESMO 2025 3 pages 163.4KB
Regulatory Filings
2025-10-19 English
Improved ORR in First Line NSCLC - presented at ESMO 2025 3 pages 187.8KB
Investor Presentation
2025-10-19 English
2025 Annual General Meeting and Key Dates 1 page 43
AGM Information
2025-10-14 English
Successful Completion of FDA Project Optimus Requirements 2 pages 153.4KB
Regulatory Filings
2025-10-12 English
Notification regarding unquoted securities - IMM 6 pages 18.6KB
Share Issue/Capital Change
2025-10-12 English
TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC 3 pages 188.0KB
Regulatory Filings
2025-10-08 English
Change of Director's Interest Notice - M Voigt 3 pages 132.4KB
Director's Dealing
2025-10-07 English
Change of Director's Interest Notice - F Triebel 3 pages 134.4KB
Director's Dealing
2025-10-07 English
Change of Director's Interest Notice - P Meyers 3 pages 134.6KB
Director's Dealing
2025-10-07 English
Application for quotation of securities - IMM 6 pages 19.3KB
Share Issue/Capital Change
2025-09-30 English
New investigator-initiated Phase II trial for Efti 2 pages 170.2KB
Regulatory Filings
2025-09-21 English
Becoming a substantial holder 18 pages 895.8KB
Major Shareholding Notification
2025-09-11 English
EFTISARC-NEO data accepted for oral presentation at CTOS 2 pages 146.4KB
Investor Presentation
2025-09-07 English
Appendix 4E & 2025 Full Year Statutory Accounts 93 pages 5.5MB
Annual Report
2025-08-28 English
FDA feedback received for head & neck cancer in CPS below 1 2 pages 108.8KB
Regulatory Filings
2025-08-04 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 563.6KB
Interim / Quarterly Report
2025-07-29 English
TACTI-004 trial in progress poster to be presented at WCLC 2 pages 260.5KB
Regulatory Filings
2025-07-28 English
Abstracts Accepted for Presentation at ESMO Congress 2025 2 pages 236.8KB
Regulatory Filings
2025-07-27 English
Ceasing to be a substantial holder 15 pages 1.0MB
Major Shareholding Notification
2025-07-24 English
Ceasing to be a substantial holder 3 pages 349.2KB
Major Shareholding Notification
2025-07-22 English
Application for quotation of securities - IMM 6 pages 18.3KB
Share Issue/Capital Change
2025-07-17 English
Application for quotation of securities - IMM 6 pages 18.3KB
Share Issue/Capital Change
2025-07-17 English
Change in substantial holding 18 pages 1.3MB
Major Shareholding Notification
2025-07-16 English
Change in substantial holding 4 pages 257.0KB
Major Shareholding Notification
2025-06-29 English
Update on Phase I Study of IMP761 for Autoimmune Diseases 2 pages 294.8KB
Regulatory Filings
2025-06-22 English
Immutep Corporate Presentation 40 pages 4.3MB
Investor Presentation
2025-06-01 English
Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial 2 pages 215.4KB
Regulatory Filings
2025-05-25 English
High Response Rates achieved in Lung Cancer in INSIGHT-003 3 pages 281.8KB
Capital/Financing Update
2025-05-14 English
Excellent Overall Survival in Head & Neck Cancer Patients 2 pages 287.2KB
Regulatory Filings
2025-05-04 English
Change in substantial holding 7 pages 104.8KB
Major Shareholding Notification
2025-04-30 English
Immutep Quarterly Activities Report and Appendix 4C 9 pages 517.9KB
Interim / Quarterly Report
2025-04-28 English
Immutep Investor Update 6 pages 636.7KB
Investor Presentation
2025-04-22 English
Change in substantial holding 21 pages 1.3MB
Regulatory Filings
2025-04-10 English
Change of Director's Interest Notice F Triebel 3 pages 134.4KB
Director's Dealing
2025-04-07 English
Change of Director's Interest Notice - M Voigt 3 pages 132.5KB
Director's Dealing
2025-04-07 English
Application for quotation of securities - IMM 6 pages 19.1KB
Share Issue/Capital Change
2025-04-02 English
Immutep to Participate in Upcoming Investor Conferences 1
Regulatory Filings
2025-04-01 English
First patient dosed in phase 3 TACTI-004 lung cancer trial 3 pages 287.8KB
Regulatory Filings
2025-03-24 English
TACTI-004 trial in progress poster to be presented at ELCC 2 pages 245.5KB
Investor Presentation
2025-03-19 English
Half Yearly Report and Accounts 30 pages 1.3MB
Interim / Quarterly Report
2025-02-25 English
Notification of cessation of securities - IMM 4 pages 14.7KB
Share Issue/Capital Change
2025-02-05 English
Immutep Corporate Presentation 39 pages 3.9MB
Investor Presentation
2025-02-04 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 397.7KB
Interim / Quarterly Report
2025-01-30 English
Enrolment completed for Ph II trial in Soft Tissue Sarcoma 2 pages 101.9KB
Regulatory Filings
2025-01-21 English
Patient Enrolment Completed for INSIGHT-003 2 pages 275.5KB
Regulatory Filings
2025-01-05 English